Bio-Rad's Q3 revenue comes slightly above estimates on Clinical Diagnostics growth

What happened

Bio-Rad reported third-quarter revenue up 0.5% from a year earlier, slightly above estimates, with Clinical Diagnostics growth leading the increase. Higher demand for Droplet Digital PCR instruments partly offset weaker Life Science sales, while lower process chromatography sales and academic research challenges weighed on that segment.

Confirmed

Global impact / market context

The small revenue increase shows that strength in diagnostics is currently helping offset pressure in Life Science. If the weaker process chromatography and academic research markets persist, they could limit sales growth, while continued diagnostics demand could support revenue and cushion that decline.

Analyst inference

Bio-Rad expects 2026 non-GAAP, currency-neutral revenue to range from down 3% to up 0.5%; non-GAAP means adjusted to exclude certain items, and currency-neutral removes exchange-rate effects. It kept its operating margin outlook, a measure of operating profit per sale, at 10% to 12%.

Confirmed

What to watch

1. Watch whether Clinical Diagnostics sales continue growing, especially in quality systems and diabetes products, since the article identifies them as the main drivers of overall revenue growth. Analyst inference
2. Track Life Science sales for signs that weaker process chromatography and academic research demand ease, as further declines could offset gains from diagnostics and digital PCR instruments. Analyst inference
3. Compare upcoming results with the 2026 revenue outlook of down 3% to up 0.5%, and check whether the company maintains its 10% to 12% operating margin outlook. Confirmed

Evidence

• Original source link unavailable